Giovanni B. Frisoni is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Giovanni B. Frisoni is a world-renowned neurologist and neuroscientist who has made fundamental contributions to Alzheimer's disease research, particularly in the areas of neuroimaging biomarkers, clinical trials, and disease modification. As a professor at the University of Geneva and former Director of the IRCCS Fatebenefratelli in Brescia, Italy, Frisoni has shaped the field of Alzheimer's diagnostics and therapeutic development[1].
With an h-index of 180 and over 700 peer-reviewed publications, Frisoni is one of the most influential researchers in neurodegenerative disease research. His work has been cited over 100,000 times[2].
- Professor of Neuroscience, University of Geneva, Switzerland
- Director, Memory Clinic, University Hospitals of Geneva
- Former Director, IRCCS Fatebenefratelli, Brescia, Italy
- Former President, European Alzheimer's Disease Consortium (EADC)
Frisoni's neuroimaging research has been groundbreaking:
- Structural MRI: Developed methods for measuring hippocampal atrophy and cortical thinning
- White matter imaging: Characterized white matter lesions and disconnection in AD
- Functional imaging: Investigated default mode network alterations in AD
¶ CSF and Blood Biomarkers
His biomarker work includes:
- CSF amyloid and [tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX--: Validated cutoffs for AD diagnosis
- Blood-based biomarkers: Pioneered plasma p-tau181 and [p-tau217[/entities/[p-tau217[/entities/[p-tau217[/entities/[p-tau217--TEMP--/entities)--FIX--
- Multimodal biomarkers: Integrated imaging and fluid markers for precision diagnosis
Frisoni has led numerous Phase II and III clinical trials:
- Anti-amyloid therapies (bapineuzumab, solanezumab, gantenerumab)
- Disease-modifying therapies
- Symptomatic treatments for cognition
-
Hippocampal Atrophy Measurement: Standardized MRI methods for measuring hippocampal atrophy in AD[3]
-
CSF Biomarker Cutoffs: Established evidence-based cutoffs for CSF amyloid and tau in AD diagnosis[4]
-
MCI Subtypes: Characterized different subtypes of mild cognitive impairment and their progression risks[5]
-
Vascular Contributions: Demonstrated the role of vascular pathology in Alzheimer's disease pathogenesis[6]
-
Preclinical AD Criteria: Contributed to defining preclinical Alzheimer's disease stages[7]
- [Alzheimer's Disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--
- [Mild Cognitive Impairment[/diseases/[mci[/diseases/[mci[/diseases/[mci--TEMP--/diseases)--FIX--
- [Vascular Dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia[/diseases/[vascular-dementia--TEMP--/diseases)--FIX--
- [Subjective Cognitive Decline[/diseases/[subjective-cognitive-decline[/diseases/[subjective-cognitive-decline[/diseases/[subjective-cognitive-decline--TEMP--/diseases)--FIX--
- [Hippocampal atrophy[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--
- [CSF biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers--TEMP--/diagnostics)--FIX--
- [Amyloid and tau[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis[/mechanisms/[amyloid-hypothesis--TEMP--/mechanisms)--FIX--
- [Brain network dysfunction[/mechanisms/[brain-networks[/mechanisms/[brain-networks[/mechanisms/[brain-networks--TEMP--/mechanisms)--FIX--
- [Vascular contributions to AD[/mechanisms/[vascular-dementia-pathogenesis[/mechanisms/[vascular-dementia-pathogenesis[/mechanisms/[vascular-dementia-pathogenesis--TEMP--/mechanisms)--FIX--
-
Neuroimaging in Alzheimer's disease. Lancet Neurol, 2010.
-
CSF biomarkers for AD diagnosis. Alzheimer's & Dementia, 2012.
-
Preclinical AD criteria. Alzheimer's & Dementia, 2011.
-
Vascular factors in AD. Neurobiol Aging, 2010.
-
MCI subtypes and progression. Neurology, 2010.
¶ Collaborators and Research Network
- [Ralf J. Rosen[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers - University of Geneva
- [Frederic Assal[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers - University Hospitals of Geneva
- [Philippe H. Robert[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers - France
- [Brian D. Hook[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers - Roche
- [Jeffrey L. Cummings[/researchers/[jeffrey-cummings[/researchers/[jeffrey-cummings[/researchers/[jeffrey-cummings--TEMP--/researchers)--FIX-- - University of Nevada
Recent work includes:
- Plasma biomarker implementation in memory clinics
- Anti-amyloid treatment effects in real-world populations
- Personalized medicine approaches in AD
- Digital health technologies for cognitive assessment
- [Researchers and Institutions Index[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers
- [Diseases Index[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
- [Mechanisms Index[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/[mechanisms[/mechanisms
- [MRI Biomarkers[/diagnostics/[mri-neurodegeneration[/diagnostics/[mri-neurodegeneration[/diagnostics/[mri-neurodegeneration--TEMP--/diagnostics)--FIX--
- [CSF Biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers[/diagnostics/[csf-biomarkers--TEMP--/diagnostics)--FIX--
- [Hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--
The study of Giovanni B. Frisoni has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
Frisoni GB, et al. (2010). "The future of Alzheimer's disease: The next 10 years." Lancet Neurol. DOI
-
Frisoni GB, et al. (2013). "Clinical trials in Alzheimer's disease: A pipeline analysis." Clin Pharmacol Ther. DOI
-
Frisoni GB, et al. (2002). "Hippocampal and entorhinal [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX-- atrophy in MCI." Neurology. DOI
-
Frisoni GB, et al. (2013). "CSF biomarkers in ADNI." Neurology. DOI
-
Petersen RC, et al. (2010). "MCI subtypes and progression." Neurology. DOI
-
Frisoni GB, et al. (2009). "Vascular pathology in AD." Neurobiol Aging. DOI
-
Sperling RA, et al. (2011). "Toward defining preclinical AD." Alzheimer's & Dementia. DOI
Page updated: 2026-03-05